;PMID: 8291265
;source_file_1734.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..188] = [t:41..188]
;2)section:[e:192..228] = [t:192..228]
;3)section:[e:232..342] = [t:232..342]
;4)sentence:[e:346..348] = [t:346..348]
;5)sentence:[e:349..623] = [t:349..623]
;6)sentence:[e:625..751] = [t:625..751]
;7)sentence:[e:752..881] = [t:752..881]
;8)sentence:[e:882..884] = [t:882..884]
;9)sentence:[e:885..998] = [t:885..998]
;10)sentence:[e:999..1173] = [t:999..1173]
;11)sentence:[e:1175..1177] = [t:1175..1177]
;12)sentence:[e:1178..1403] = [t:1178..1403]
;13)sentence:[e:1404..1406] = [t:1404..1406]
;14)sentence:[e:1407..1614] = [t:1407..1614]
;15)sentence:[e:1615..1617] = [t:1615..1617]
;16)sentence:[e:1618..1919] = [t:1618..1919]
;17)section:[e:1923..1967] = [t:1923..1967]

;section 0 Span:0..35
;Xenobiotica. 1993 Sep;23(9):973-82.
(SEC
  (FRAG (NNP:[0..11] Xenobiotica) (,:[11..12] .) (CD:[13..17] 1993)
        (CC:[18..25] Sep;23-LRB-) (CD:[25..26] 9) (-RRB-:[26..27] -RRB-)
        (::[27..28] :) (CD:[28..31] 973) (::[31..32] -) (CD:[32..34] 82)
        (.:[34..35] .)))

;sentence 1 Span:41..188
;Microbial models of mammalian metabolism: involvement of cytochrome P450 in
;the  N-demethylation of N-methylcarbazole by Cunninghamella echinulata.
;[98..113]:cyp450:"cytochrome P450"
;[141..158]:substance:"N-methylcarbazole"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[41..50] Microbial) (NNS:[51..57] models))
      (PP (IN:[58..60] of)
        (NP (JJ:[61..70] mammalian) (NN:[71..81] metabolism))))
    (::[81..82] :)
    (NP
      (NP (NN:[83..94] involvement))
      (PP (IN:[95..97] of)
        (NP (NN:[98..108] cytochrome) (NN:[109..113] P450)))
      (PP (IN:[114..116] in)
        (NP
          (NP (DT:[117..120] the) (NN:[122..137] N-demethylation))
          (PP (IN:[138..140] of)
            (NP (NN:[141..158] N-methylcarbazole)))
          (PP (IN:[159..161] by)
            (NP (NNP:[162..176] Cunninghamella) (NNP:[177..187] echinulata))))))
    (.:[187..188] .)))

;section 2 Span:192..228
;Yang W, Jiang T, Acosta D, Davis PJ.
(SEC
  (FRAG (NNP:[192..196] Yang) (NNP:[197..198] W) (,:[198..199] ,)
        (NNP:[200..205] Jiang) (NNP:[206..207] T) (,:[207..208] ,)
        (NNP:[209..215] Acosta) (NNP:[216..217] D) (,:[217..218] ,)
        (NNP:[219..224] Davis) (NNP:[225..228] PJ.)))

;section 3 Span:232..342
;Division of Medicinal and Natural Products Chemistry, College of Pharmacy, 
;University of Texas, Austin 78712.
(SEC
  (FRAG (NNP:[232..240] Division) (IN:[241..243] of) (NNP:[244..253] Medicinal)
        (CC:[254..257] and) (NNP:[258..265] Natural) (NNP:[266..274] Products)
        (NNP:[275..284] Chemistry) (,:[284..285] ,) (NNP:[286..293] College)
        (IN:[294..296] of) (NNP:[297..305] Pharmacy) (,:[305..306] ,)
        (NNP:[308..318] University) (IN:[319..321] of) (NNP:[322..327] Texas)
        (,:[327..328] ,) (NNP:[329..335] Austin) (CD:[336..341] 78712)
        (.:[341..342] .)))

;sentence 4 Span:346..348
;1.
(SENT
  (NP (LS:[346..348] 1.)))

;sentence 5 Span:349..623
;As previously reported (Yang and Davis 1992), N-methylcarbazole (NMC) is 
;converted to N-hydroxymethylcarbazole (NHMC), and 
;3-hydroxy-N-hydroxymethylcarbazole (3-OH-NHMC), two relatively stable 
;carbinolamine metabolites by the fungus Cunninghamella echinulata (ATCC
;9244).
;[395..412]:substance:"N-methylcarbazole"
;[414..417]:substance:"NMC"
;[436..460]:substance:"N-hydroxymethylcarbazole"
;[462..466]:substance:"NHMC"
;[474..508]:substance:"3-hydroxy-N-hydroxymethylcarbazole"
;[510..519]:substance:"3-OH-NHMC"
;[545..570]:substance:"carbinolamine metabolites"
(SENT
  (S
    (PP (IN:[349..351] As)
      (S-NOM
        (NP-SBJ (-NONE-:[351..351] *))
        (VP
          (ADVP-TMP (RB:[352..362] previously))
          (VBN:[363..371] reported)
          (FRAG (-LRB-:[372..373] -LRB-) (NNP:[373..377] Yang)
                (CC:[378..381] and) (NNP:[382..387] Davis) (CD:[388..392] 1992)
                (-RRB-:[392..393] -RRB-)))))
    (,:[393..394] ,)
    (NP-SBJ-1
      (NP (NN:[395..412] N-methylcarbazole))
      (NP (-LRB-:[413..414] -LRB-) (NN:[414..417] NMC) (-RRB-:[417..418] -RRB-)))
    (VP (VBZ:[419..421] is)
      (VP (VBN:[423..432] converted)
        (NP-1 (-NONE-:[432..432] *))
        (PP-CLR (TO:[433..435] to)
          (NP
            (NP
              (NP
                (NP (NN:[436..460] N-hydroxymethylcarbazole))
                (NP (-LRB-:[461..462] -LRB-) (NN:[462..466] NHMC)
                    (-RRB-:[466..467] -RRB-)))
              (,:[467..468] ,) (CC:[469..472] and)
              (NP
                (NP (NN:[474..508] 3-hydroxy-N-hydroxymethylcarbazole))
                (NP (-LRB-:[509..510] -LRB-) (NN:[510..519] 3-OH-NHMC)
                    (-RRB-:[519..520] -RRB-))))
            (,:[520..521] ,)
            (NP (CD:[522..525] two)
              (ADJP (RB:[526..536] relatively) (JJ:[537..543] stable))
               (NN:[545..558] carbinolamine) (NNS:[559..570] metabolites))))
        (PP (IN:[571..573] by)
          (NP-LGS
            (NP
              (NP (DT:[574..577] the) (NN:[578..584] fungus))
              (NP (NNP:[585..599] Cunninghamella) (NNP:[600..610] echinulata)))
            (NP (-LRB-:[611..612] -LRB-) (NN:[612..616] ATCC)
                (CD:[617..621] 9244) (-RRB-:[621..622] -RRB-))))))
    (.:[622..623] .)))

;sentence 6 Span:625..751
;Decomposition of these two carbinolamines yields the corresponding
;dealkylated  metabolites, carbazole and 3-hydroxycarbazole.
;[652..666]:substance:"carbinolamines"
;[705..716]:substance:"metabolites"
;[718..727]:substance:"carbazole"
;[732..750]:substance:"3-hydroxycarbazole"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[625..638] Decomposition))
      (PP (IN:[639..641] of)
        (NP (DT:[642..647] these) (CD:[648..651] two)
            (NNS:[652..666] carbinolamines))))
    (VP (VBZ:[667..673] yields)
      (NP
        (NP (DT:[674..677] the) (VBG:[678..691] corresponding)
            (VBN:[692..703] dealkylated) (NNS:[705..716] metabolites))
        (,:[716..717] ,)
        (NP (NN:[718..727] carbazole) (CC:[728..731] and)
            (NN:[732..750] 3-hydroxycarbazole))))
    (.:[750..751] .)))

;sentence 7 Span:752..881
;In the present study, the  possible involvement of cytochrome P450 in the
;requisite N-alkyl hydroxylation  reaction was examined.
;[803..818]:cyp450:"cytochrome P450"
(SENT
  (S
    (PP-LOC (IN:[752..754] In)
      (NP (DT:[755..758] the) (JJ:[759..766] present) (NN:[767..772] study)))
    (,:[772..773] ,)
    (NP-SBJ-1
      (NP (DT:[774..777] the) (JJ:[779..787] possible)
          (NN:[788..799] involvement))
      (PP (IN:[800..802] of)
        (NP (NN:[803..813] cytochrome) (NN:[814..818] P450)))
      (PP (IN:[819..821] in)
        (NP (DT:[822..825] the) (JJ:[826..835] requisite)
          (NML (NN:[836..843] N-alkyl) (NN:[844..857] hydroxylation))
          (NN:[859..867] reaction))))
    (VP (VBD:[868..871] was)
      (VP (VBN:[872..880] examined)
        (NP-1 (-NONE-:[880..880] *))))
    (.:[880..881] .)))

;sentence 8 Span:882..884
;2.
(SENT
  (NP (LS:[882..884] 2.)))

;sentence 9 Span:885..998
;Carbon monoxide, a classical P450 inhibitor, markedly  inhibited the
;formation of NHMC, as did potassium cyanide.
;[885..900]:substance:"Carbon monoxide"
;[914..918]:cyp450:"P450"
;[919..928]:substance:"inhibitor"
;[967..971]:substance:"NHMC"
;[980..997]:substance:"potassium cyanide"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[885..891] Carbon) (NN:[892..900] monoxide))
      (,:[900..901] ,)
      (NP (DT:[902..903] a) (JJ:[904..913] classical) (NN:[914..918] P450)
          (NN:[919..928] inhibitor)))
    (,:[928..929] ,)
    (ADVP-MNR (RB:[930..938] markedly))
    (VP (VBD:[940..949] inhibited)
      (NP
        (NP (DT:[950..953] the) (NN:[954..963] formation))
        (PP (IN:[964..966] of)
          (NP (NN:[967..971] NHMC))))
      (,:[971..972] ,)
      (SBAR (IN:[973..975] as)
        (SINV
          (VP (VBD:[976..979] did)
            (VP (-NONE-:[979..979] *?*)))
          (NP-SBJ (NN:[980..989] potassium) (NN:[990..997] cyanide)))))
    (.:[997..998] .)))

;sentence 10 Span:999..1173
;1-Benzylimidazole,  piperonyl butoxide and SKF-525A inhibited the formation
;of both NHMC and  3-OH-NHMC, while beta-naphthoflavone (5,6-benzoflavone)
;induced their formation.
;[999..1016]:substance:"1-Benzylimidazole"
;[1019..1037]:substance:"piperonyl butoxide"
;[1042..1050]:substance:"SKF-525A"
;[1083..1087]:substance:"NHMC"
;[1093..1102]:substance:"3-OH-NHMC"
;[1110..1129]:substance:"beta-naphthoflavone"
;[1131..1147]:substance:"5,6-benzoflavone"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[999..1016] 1-Benzylimidazole))
      (,:[1016..1017] ,)
      (NP (NN:[1019..1028] piperonyl) (NN:[1029..1037] butoxide))
      (CC:[1038..1041] and)
      (NP (NN:[1042..1050] SKF-525A)))
    (VP (VBD:[1051..1060] inhibited)
      (NP
        (NP (DT:[1061..1064] the) (NN:[1065..1074] formation))
        (PP (IN:[1075..1077] of)
          (NP (CC:[1078..1082] both) (NN:[1083..1087] NHMC)
              (CC:[1088..1091] and) (NN:[1093..1102] 3-OH-NHMC))))
      (,:[1102..1103] ,)
      (SBAR-ADV (IN:[1104..1109] while)
        (S
          (NP-SBJ
            (NP (NN:[1110..1129] beta-naphthoflavone))
            (NP (-LRB-:[1130..1131] -LRB-) (NN:[1131..1147] 5,6-benzoflavone)
                (-RRB-:[1147..1148] -RRB-)))
          (VP (VBD:[1149..1156] induced)
            (NP (PRP$:[1157..1162] their) (NN:[1163..1172] formation))))))
    (.:[1172..1173] .)))

;sentence 11 Span:1175..1177
;3.
(SENT
  (NP (LS:[1175..1177] 3.)))

;sentence 12 Span:1178..1403
;The source of the oxygen atom in the metabolite NHMC was examined by GC/MS 
;analysis of NHMC formed during incubation of NMC in H218O-enriched medium
;which  resulted in no incorporation of labelled oxygen into the metabolite.
;[1196..1202]:substance:"oxygen"
;[1215..1225]:substance:"metabolite"
;[1226..1230]:substance:"NHMC"
;[1266..1270]:substance:"NHMC"
;[1299..1302]:substance:"NMC"
;[1306..1311]:substance:"H218O"
;[1321..1327]:substance:"medium"
;[1376..1382]:substance:"oxygen"
;[1392..1402]:substance:"metabolite"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1178..1181] The) (NN:[1182..1188] source))
      (PP (IN:[1189..1191] of)
        (NP (DT:[1192..1195] the) (NN:[1196..1202] oxygen)
            (NN:[1203..1207] atom)))
      (PP-LOC (IN:[1208..1210] in)
        (NP (DT:[1211..1214] the) (NN:[1215..1225] metabolite)
            (NN:[1226..1230] NHMC))))
    (VP (VBD:[1231..1234] was)
      (VP (VBN:[1235..1243] examined)
        (NP-2 (-NONE-:[1243..1243] *))
        (PP-MNR (IN:[1244..1246] by)
          (NP
            (NP
              (NML (NN:[1247..1249] GC) (SYM:[1249..1250] /)
                   (NN:[1250..1252] MS))
              (NN:[1254..1262] analysis))
            (PP (IN:[1263..1265] of)
              (NP
                (NP (NN:[1266..1270] NHMC))
                (VP (VBN:[1271..1277] formed)
                  (NP (-NONE-:[1277..1277] *))
                  (PP-TMP (IN:[1278..1284] during)
                    (NP
                      (NP
                        (NP (NN:[1285..1295] incubation))
                        (PP (IN:[1296..1298] of)
                          (NP (NN:[1299..1302] NMC)))
                        (PP-LOC (IN:[1303..1305] in)
                          (NP
                            (ADJP (NN:[1306..1311] H218O) (HYPH:[1311..1312] -)
                                  (VBN:[1312..1320] enriched))
                            (NN:[1321..1327] medium))))
                      (SBAR
                        (WHNP-1 (WDT:[1328..1333] which))
                        (S
                          (NP-SBJ-1 (-NONE-:[1333..1333] *T*))
                          (VP (VBD:[1335..1343] resulted)
                            (PP-CLR (IN:[1344..1346] in)
                              (NP
                                (NP (DT:[1347..1349] no)
                                    (NN:[1350..1363] incorporation))
                                (PP (IN:[1364..1366] of)
                                  (NP (VBN:[1367..1375] labelled)
                                      (NN:[1376..1382] oxygen)))
                                (PP (IN:[1383..1387] into)
                                  (NP (DT:[1388..1391] the)
                                      (NN:[1392..1402] metabolite)))))))))))))))))
    (.:[1402..1403] .)))

;sentence 13 Span:1404..1406
;4.
(SENT
  (NP (LS:[1404..1406] 4.)))

;sentence 14 Span:1407..1614
;An  intermolecular isotope effect was not observed for the formation of NHMC 
;suggesting that C-H bond cleavage is not a rate limiting step in the
;formation  of this metabolite under the conditions examined.
;[1479..1483]:substance:"NHMC"
;[1573..1583]:substance:"metabolite"
(SENT
  (S
    (NP-SBJ-1 (DT:[1407..1409] An) (JJ:[1411..1425] intermolecular)
              (NN:[1426..1433] isotope) (NN:[1434..1440] effect))
    (VP (VBD:[1441..1444] was) (RB:[1445..1448] not)
      (VP (VBN:[1449..1457] observed)
        (NP-1 (-NONE-:[1457..1457] *))
        (PP (IN:[1458..1461] for)
          (NP
            (NP (DT:[1462..1465] the) (NN:[1466..1475] formation))
            (PP (IN:[1476..1478] of)
              (NP (NN:[1479..1483] NHMC)))))
        (S-ADV
          (NP-SBJ (-NONE-:[1483..1483] *))
          (VP (VBG:[1485..1495] suggesting)
            (SBAR (IN:[1496..1500] that)
              (S
                (NP-SBJ
                  (NML
                    (NML (NN:[1501..1502] C) (HYPH:[1502..1503] -)
                         (NN:[1503..1504] H))
                    (NN:[1505..1509] bond))
                  (NN:[1510..1518] cleavage))
                (VP (VBZ:[1519..1521] is) (RB:[1522..1525] not)
                  (NP-PRD
                    (NP (DT:[1526..1527] a)
                      (ADJP (NN:[1528..1532] rate) (VBG:[1533..1541] limiting))
                      (NN:[1542..1546] step))
                    (PP (IN:[1547..1549] in)
                      (NP
                        (NP (DT:[1550..1553] the) (NN:[1554..1563] formation))
                        (PP (IN:[1565..1567] of)
                          (NP (DT:[1568..1572] this)
                              (NN:[1573..1583] metabolite)))
                        (PP (IN:[1584..1589] under)
                          (NP
                            (NP (DT:[1590..1593] the)
                                (NNS:[1594..1604] conditions))
                            (VP (VBN:[1605..1613] examined)
                              (NP (-NONE-:[1613..1613] *)))))))))))))))
    (.:[1613..1614] .)))

;sentence 15 Span:1615..1617
;5.
(SENT
  (NP (LS:[1615..1617] 5.)))

;sentence 16 Span:1618..1919
;It was concluded that P450  enzymes may be involved in the N-demethylation of
;NMC catalyzed by this fungal  model of mammalian metabolism, and provides
;further support for biochemical and  mechanistic parallels between mammalian
;metabolism and microbial systems  catalyzing phase-1 biotransformations.
;[1640..1653]:cyp450:"P450  enzymes"
;[1696..1699]:substance:"NMC"
(SENT
  (S
    (NP-SBJ-3
      (NP (PRP:[1618..1620] It))
      (SBAR-4 (-NONE-:[1620..1620] *EXP*)))
    (VP
      (VP (VBD:[1621..1624] was)
        (VP (VBN:[1625..1634] concluded)
          (NP-3 (-NONE-:[1634..1634] *))
          (SBAR-4 (IN:[1635..1639] that)
            (S
              (NP-SBJ-2 (NN:[1640..1644] P450) (NNS:[1646..1653] enzymes))
              (VP (MD:[1654..1657] may)
                (VP (VB:[1658..1660] be)
                  (VP (VBN:[1661..1669] involved)
                    (NP-2 (-NONE-:[1669..1669] *))
                    (PP-CLR (IN:[1670..1672] in)
                      (NP
                        (NP
                          (NP (DT:[1673..1676] the)
                              (NN:[1677..1692] N-demethylation))
                          (PP (IN:[1693..1695] of)
                            (NP (NN:[1696..1699] NMC))))
                        (VP (VBN:[1700..1709] catalyzed)
                          (NP (-NONE-:[1709..1709] *))
                          (PP (IN:[1710..1712] by)
                            (NP-LGS
                              (NP (DT:[1713..1717] this)
                                  (JJ:[1718..1724] fungal)
                                  (NN:[1726..1731] model))
                              (PP (IN:[1732..1734] of)
                                (NP (JJ:[1735..1744] mammalian)
                                    (NN:[1745..1755] metabolism)))))))))))))))
      (,:[1755..1756] ,) (CC:[1757..1760] and)
      (VP (VBZ:[1761..1769] provides)
        (NP
          (NP (JJR:[1770..1777] further) (NN:[1778..1785] support))
          (PP (IN:[1786..1789] for)
            (NP
              (NP
                (NP (JJ:[1790..1801] biochemical)
                  (NML-1 (-NONE-:[1801..1801] *P*)))
                (CC:[1802..1805] and)
                (NP (JJ:[1807..1818] mechanistic)
                  (NML-1 (NNS:[1819..1828] parallels))))
              (PP (IN:[1829..1836] between)
                (NP
                  (NP (JJ:[1837..1846] mammalian) (NN:[1847..1857] metabolism))
                  (CC:[1858..1861] and)
                  (NP
                    (NP (JJ:[1862..1871] microbial) (NNS:[1872..1879] systems))
                    (VP (VBG:[1881..1891] catalyzing)
                      (NP (NN:[1892..1899] phase-1)
                          (NNS:[1900..1918] biotransformations)))))))))))
    (.:[1918..1919] .)))

;section 17 Span:1923..1967
;PMID: 8291265 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1923..1927] PMID) (::[1927..1928] :) (CD:[1929..1936] 8291265)
        (NN:[1937..1938] -LSB-) (NNP:[1938..1944] PubMed) (::[1945..1946] -)
        (NN:[1947..1954] indexed) (IN:[1955..1958] for)
        (NNP:[1959..1967] MEDLINE-RSB-)))
